Use of neurotoxin therapy for treatment of urologic and related disorders

Details for Australian Patent Application No. 2006225233 (hide)

Owner The Regents of the University of Colorado

Inventors Schmidt, Richard A.

Agent Davies Collison Cave

Pub. Number AU-B-2006225233

Parent 2005234633

Filing date 4 October 2006

Wipo publication date 26 October 2006

Acceptance publication date 7 December 2006

International Classifications

A61K 35/74 (2006.01) Medicinal preparations containing material or reaction products thereof with undetermined constitution

A61P 13/10 (2006.01) Drugs for disorders of the urinary system

Event Publications

19 October 2006 Complete Application Filed

26 October 2006 Application Open to Public Inspection

  Published as AU-B-2006225233

7 December 2006 Application Accepted

  Published as AU-B-2006225233

22 March 2007 Opposition Lodged

  Societe de Conseils de Recherches et D'Applications Scientifique (S.C.R.A.S.) has lodged an opposition against The Regents of the University of Colorado.

2 September 2010 Alteration of Name

  The name of the applicant has been altered to The Regents of the University of Colorado, a body corporate 2008

21 October 2010 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 24 Jun 2010. Address for service in Australia - Davies Collison Cave 255 Elizabeth Street Sydney NSW 2000

10 February 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 24 Jun 2010

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006225234-Shock-interference vortex muffler

2006225232-Compositions of estrogen-cyclodextrin complexes